Tourmaline Bio, Inc. is a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. Their pipeline includes a human anti-IL-6 monoclonal antibody for autoimmune and inflammatory disorders, as well as therapies for atherosclerotic cardiovascular disease and thyroid eye disease.

Tourmaline is a late-stage clinical biotechnology company driven by our mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. In doing so, we seek to develop assets medicines that have the potential to establish new standards-of-care in areas of high unmet medical need.

Tourmaline Bio

Tourmaline CEO Sandeep Kulkarni will take part in a fireside chat today at 1:00 PM ET at the Piper Sandler 35th Annual Virtual Healthcare Conference.

To listen to the webcast, please visit: https://lnkd.in/eGYp3Pb7
 
 #Tourmaline #Immunology #TeamTourmaline #PSCHealthcare2023

Tourmaline CEO Sandeep Kulkarni will take part in a fireside chat today at 3:50 PM ET at the Guggenheim Partners 5th Annual I&I Conference.
 
To listen to the webcast, please visit: https://lnkd.in/eGYp3Pb7
 
 #Tourmaline #Immunology #TeamTourmaline #Guggenheim

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.

TRML

COM:TOURMALINEBIO

Tourmaline Bio, Inc.

Last Close

23.50

20/11 21:00

Market Cap

352.13M

Beta: -

Volume Today

154.31K

Avg: -

Analysis Not Available